Mereo BioPharma Group Under Class Action for Securities Fraud

DJS Law Group is alerting investors to a class action lawsuit against Mereo BioPharma Group that involves allegations of violations of the Securities Exchange Act sections 10(b) and 20(a). These violations pertain to shareholders who bought shares between June 5, 2023, and December 26, 2025. The lawsuit claims that Mereo provided false and deceptive information about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their intended goals against placebo or bisphosphonate control groups, leading investors astray during the entire class period.

Investors who incurred losses due to these actions are encouraged to reach out to DJS Law Group to participate in the lawsuit. While becoming a lead plaintiff is optional, those who choose to do so have the opportunity to pursue a measure of recovery. This legal action may have significant financial ramifications for the company involved.

DJS Law Group is dedicated to helping investors maximize their returns by offering sound advice and robust representation. Specializing in securities class actions and corporate governance litigation, the firm is committed to delivering top-tier legal services to its clientele.

Another legal entity, the Rosen Law Firm, has initiated a class action lawsuit against Mereo BioPharma Group plc. This lawsuit involves individuals who acquired American Depositary Shares between June 5, 2023, and December 26, 2025. The legal action aims to seek redress for affected investors and could pose substantial legal risks for the company in question.

The allegations against Mereo BioPharma involve misleading statements about the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary targets related to minimizing clinical fracture rates. Upon the revelation of the true outcomes, investors suffered financial losses, underscoring significant shortcomings in the company’s research and development strategies.

Investors looking to join the class action need not worry about upfront expenses, as Rosen Law Firm operates on a contingency fee basis. This fee structure mitigates financial risks for investors, potentially attracting more affected parties to participate. With its strong record in securities class actions—having reclaimed over $438 million for investors in 2019 alone—the law firm is well-equipped to handle cases similar to this one.

Furthermore, Bronstein, Gewirtz & Grossman, LLC has also initiated a class action lawsuit against Mereo BioPharma Group. This legal action seeks to secure damages for investors who bought Mereo securities during the specified period. The lawsuit contends that Mereo provided overly optimistic statements while concealing key negative information about the Phase 3 ORBIT and COSMIC programs, which ultimately influenced investors’ views on the company.

The failure of Mereo’s pivotal clinical trials to achieve their intended objectives could have adverse effects on the company’s future performance in the market. Investors impacted by these events have until April 6, 2026, to request to be a lead plaintiff, indicating the timeliness and proactive nature of investors in this legal process.

In light of these legal developments, Faruq & Faruqi, LLP is currently investigating potential claims against Mereo BioPharma Group plc for investors who bought securities in the relevant time frame. Investors are reminded of the April 6, 2026, deadline to seek the role of lead plaintiff in a federal securities class action if they suffered financial losses. This legal inquiry could potentially impact Mereo’s stock price and investor confidence, reflecting broader market concerns regarding the company’s future operations and performance.

In conclusion, these class action lawsuits underscore the importance of transparency and integrity in the corporate world. Investors affected by misleading or false statements deserve a fair chance to seek redress through legal channels that uphold investor rights and safeguard financial interests.